Progress CARDIOVASCULAR
in DISEASES
EDMUND H. SONNENBLICK, M.D., Editor MICHAEL LESCH, M.D., Co-Editor Charles K. Friedberg, M.D., Founding Editor
VOLUME
XXI,
1978-1979
No. 1 (July/August) ECHOCARDIOGRAPHY. Echocardiography for the Evaluation and Atrium.........................................
of the Tricuspid
III.
Valve, Right Ventricle,
Masapuki
Matsumoto
Ultrasonic Assessmentof Transposition of the Great Vessels .
Special
.
Matsuo
I
. RaJwzond Grarniak and Navin C. Nanda
43
and Hirohide
A rticle
Natural History of Obstructive Coronary Artery Disease: Ten-Year Study of 60 I Nonsurgical Cases.. . .. . . . .. . . .. . . . .. . . . .. . . William L. Proudjt, Albert V. G. Bruschke, and F. Mason
Sones. Jr.
53
W. Baker
79
and C. M. Ouklej-
92
No. 2 (September/October) ECHOCARDIOGRAPHY.
IV.
The Present Role of Doppler Techniques in Cardiac Diagnosis.. . Echocardiographic Evaluation of the Mitral Valve . .
.
,.
..
. R. B. Pridie
. Donald
The Use of Echocardiography for Quantitative Evaluation of Left Ventricular Function Steven J. Mason
Echocardiographic Evaluation of Pericardial Diseases . . . Special
.
.
and Nicholas . .Louis
J. Fortuin
Evan Teichholz
1 19 I 33
Article
Clinical Pharmacokinetics of Digitalis Glycosides.. . . . . . . . .James E. Doherty, James J. Kane, Joe K. Bissett,
and Marvin
N. de So~~za, L. Murphy
141
No. 3 (November/December) CAPTOPRIL The Renin System in High Blood Pressure, From Disbelief to Reality: Converting-Enqme Blockade for Analysis and Treatment . . . . . .John H. Laragh Physiologic,
Biochemical,
and Immunologic
Design of New Antihypertensive Converting Enzyme . ..
Aspects of Angiotensin-Converting Enzyme Richard L. Sqfer and Edmund H. Sonnenhlick
Drugs: Potent and Specific Inhibitors of AngiotensinDavid W. Cushman. Hong Son Cheung, Emil)! F. Saho, and Miguel ,4. Ondetti
I59 167
176
Captopril (SQ 14,225) (D-3-Mercapto-2-Methylpropanoyl-[.-Proline): A Novel Orally Active Inhibitor of Angiotensin-Converting Enzyme and Antihypertensive Agent Bernard Rubin. Michael J. Antonaccio. and Zola P. Horowitz
1x3
Clinical Experience With Blockade of the Renin-Angiotensin-Aldosterone System by an Oral Converting-Enzyme Inhibitor (SQ 14,225, Captopril) in Hypertensive Patients David B. Case. Steven A. Atlas, John H. Laragh. Jean E. Sealql~. Patric,ia .4. Sullivun. and Doris N. McKin.qtr,~
195
Special Article Ultrastructural
Features of Hypertrophied
Human Ventricular Myocardium Barr,, J. Maron and Victor J. Ferran.c
207
No. 4 (January/February) FIBRINOLYSIS.
Symposium
on Fibrinolysis:
The Fibrinolytic
System-Basic
The Role of the Fibrinolytic Natural
Inhibitors
Introduction Considerations
.
I.
HUM C. Kbaan
239
. . Francis J. Castellino and Bernard N. Violand
24 l
. _,
System in Thromboembolism
_.
. . . Joseph G. Vermylen and Dalton A. F. Chamone
255
Nobuo Aoki
267
Against Ventricular Fibrillation in Acute Myocardial Infarction Hillel S. Ribner. Ellen S. Isaacs, and William H. Frishman
287
of Fibrinolysis
.
. . . . . . . . . . . .._........................................
Special Article Lidocaine
Prophylaxis
No. 5 (March/April) FIBRINOLYSIS. Pharmacology
of Fibrinolytic
Guidelines for Thrombolytic
Agents..
..................................................................
Therapy of Deep-Vein Thrombosis
Thrombolytic
Therapy of Pulmonary
Thromboembolism
Thrombolytic
Therapy in Myocardial
Infarction..
Thrombolytic
Therapy in Arterial
Synthetic
Fibrinolytic
Fibrinolysis-A
II. H. Barlow
3 15
Victor J. Marder
327
Grant
........................
......................................
Edward
..........................................................
Thromboembolism
333
F. Duckert
342
M. Martin of H. Auel)
35 1
John F. Davidson and lsobel D. Walker
375
.................................................... (with the technical supervision
Agents.. .........................................
Genton
Perspective ......................................................................................
Hau C. Ktilaan
397
No. 6 (May/June) SPECIAL Prostaglandins, Their Intermediates Roles in Normal and Abnormal
ARTICLES
and Precursors: Cardiovascular Actions and Regulatory Circulatory Systems . .. .. .. ... ..._......._......... Gregor]* J. Dusting, Salvador Moncada, and John R. Vane
405
and Predictive Capacity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M. H. Ellestad, Bernard M. Cooke, Jr., and Paul S. Greenberg
43 1
Infarction .. .. .. .. ... .. .. .. ... .. . ... .. Arthur C. For. Ephraim Classman. and 0. Wayne Isom
461
Annual Indexes .. .. .. ... .. .. .. ... . .. ... .. .. .. ... .. .. .. .. .. ... .. . ... .. .. .. ... .. .. .. .. ... .. .. .. .. ... .. .. .. ... . ... .. .. .. .. ... .. .. .. .. ... .. ..........
485
Stress Testing: Clinical Application Surgically
Remediable Complications
of Myocardial